{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-012952","form_type":"8-K","ticker":"DRMA","cik":"0001853816","company_name":"Dermata Therapeutics, Inc.","filed_at":"2025-09-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.373508+00:00","generated_at":"2026-05-17T07:06:15.874905+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Dermata pivots to OTC dermatology, withdraws XYNGARI IND, plans acne kit launch mid-2026","bullets":["Strategic shift to prioritize OTC dermatology products sold directly to consumers.","Initial focus on once-weekly acne kit using approved monograph active ingredient and Spongilla technology.","Plans to launch the acne kit in mid-2026 with additional OTC products to follow.","Withdrew its investigational new drug application for XYNGARI with the FDA.","Aims to accelerate commercialization path and reduce regulatory burdens."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-012952","json":"https://secwatch.observer/filing/0001493152-25-012952.json","markdown":"https://secwatch.observer/filing/0001493152-25-012952.md","text":"https://secwatch.observer/filing/0001493152-25-012952.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853816/000149315225012952/0001493152-25-012952-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853816/000149315225012952/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T07:06:15.874905+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}